烏龍製藥 URGN 深 滬
等待開盤 08-08 09:30:00 美东时间
18.59
-1.420
-7.10%
華盛通- 最 高19.76
- 今 開19.33
- 成交量 182.60万股
- 最 低 17.07
- 昨 收 20.01
- 總市值 8.57亿
- 52周最高 21.015
- 市盈率 靜 --
- 換手率 3.96%
- 52周最低 3.42
- 委 比 -92.78%
- 總股本 4610.75万
- 歷史最高 69.568
- 量 比 1.56
- 振 幅 13.44%
- 歷史最低 3.42
- 每 手 1
- 風險率 1.94%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Earnings Scheduled For August 7, 2025
Companies Reporting Before The Bell • GoHealth (NASDAQ:GOCO) is estimated to re...
08-07 16:33
UroGen Pharma Announces 24-Month DOR Of 72.2% By Kaplan-Meier Estimate In Patients Who Achieved CR At Three Months From Phase 3 ENVISION Trial Of ZUSDURI For Intravesical Solution
24-month Duration of Response (DOR) of 72.2% by Kaplan-Meier estimate was attained in patients who achieved a complete response (CR) at three months (79.6%)PRINCETON, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- UroGen Pharma
08-05 20:07
UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025
UroGen Pharma Ltd. will report its second quarter 2025 financial results on August 7, 2025, followed by a live webcast and conference call at 10:00 AM ET. The webcast will be available on UroGen’s Investor Relations website, with a replay accessible for 30 days. UroGen specializes in developing innovative treatments for urothelial and specialty cancers using its RTGel reverse-thermal hydrogel technology.
07-29 12:00
UroGen Pharma Announces Publication In Reviews In Urology Of Results From Phase 3b Study Evaluating Feasibility Of Administering ZUSDURI For Intravesical Solution In Home Setting
UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative treatments for urothelial and specialty cancers, today announced the publication in Reviews in Urology of results
07-28 20:08
UroGen Announces Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI™ in Patients with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
UroGen Pharma announced the publication of results from a five-year long-term extension study of the Phase 2b OPTIMA II trial evaluating ZUSDURI (mitomycin) for intravesical solution in patients with low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The study demonstrated durable, long-term complete responses (CRs) in patients who achieved initial CR with ZUSDURI. Among 17 patients entering long-term follow-up, the med...
07-21 12:00
UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
UroGen Pharma Ltd. announced the completion of patient enrollment in its Phase 3 UTOPIA clinical trial for UGN-103, a next-generation formulation of mitomycin for the treatment of recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The trial enrolled 99 patients globally and utilizes UroGen’s RTGel technology, offering potential improvements over ZUSDURI, including simplified manufacturing and reconstitution pr...
07-07 12:00
UroGen Pharma Approves Bonuses After FDA Approval
Urogen Pharma ( ($URGN) ) has shared an update. On June 30, 2025, UroGen Pharma...
07-04 04:50
EXCLUSIVE: Telomir Pharmaceuticals Says Preclinical Drug Candidate Prevents Premature Aging In Patient-Derived Cells From Children With Progeria
Telomir-1 improved cell survival, reduced oxidative stress, and restored mitochondrial balance in preclinical progeria study.
06-18 21:00
【爱建医药】ADA 2025蓄势待发，关注减肥药赛道
（转自：爱建证券研究所） ADA 2025 蓄势待发，关注 减肥药赛道 -爱建生物医药行业周报- 本报告发布于2025年06月17日 投资要...
06-18 10:28
美股机会日报丨段永平“晒单”卖出苹果看跌期权！Circle盘前再涨8%！零售巨头探索发行稳定币
段永平捞底苹果！“晒单”卖出144万美元看跌期权；Circle盘前再涨8%！沃尔玛、亚马逊探索发行稳定币；高盛唱多中国“十巨头”股票>>
06-16 20:00
